China approves satricabtagene autoleucel, the first CAR T-cell therapy for solid tumors, for claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer.
- 1 cited this week
- In the news
CAR-T cell therapy research
Moving in Cancer Discovery and Blood.
- Moved, week to 22 Oct 2026
- 3
- Papers in 60 days
- 47
Add CAR-T cell therapy research as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
In vivo CAR T-cell therapy KLN-1010 achieved a 100% overall response rate in all 18 multiple myeloma patients in a phase I trial.
- In the news
CD19 CAR T-cell therapy without lymphodepletion shows promising safety and efficacy in pemphigus vulgaris patients, with significant disease improvement in all four cases.
- Open access
- 4 cites
Latest in CAR-T cell therapy research
Newest first · last 60 days
TCR T cells targeting IgA- and IgG-expressing multiple myeloma eliminate HLA-A∗02:01+ MM cells in vitro and in vivo, showing promise for therapy in about 40% of European descent patients.
- Open access
- 1 cites
Rapid peak cilta-cel expansion is linked to increased risk of delayed neurotoxicity in patients with relapsed/refractory multiple myeloma.
CAR-engineered microglia selectively eliminate GBM cells through phagocytosis in organoid models, showing increased phagocytic activity and tumor transcript internalization.
- Open access
TLR9-activated B cells enhance CD8+ T-cell antitumor activity via a CD2-dependent costimulation axis in cancer therapy.
- Open access
The ITCC-P4 platform established 353 molecularly characterized pediatric cancer PDX models for in vivo drug testing, capturing tumor heterogeneity and disease progression.
- Open access
CAR-T cell therapy and cancer nanovaccines are emerging as powerful, potentially complementary immunotherapy strategies with distinct strengths and limitations across studies.
- Open access
CD19 CAR T cell therapy demonstrated acceptable safety and significant clinical improvements in six patients with treatment-refractory seropositive rheumatoid arthritis, with a median 34% DAS28-CRP reduction.
CD19-targeted CAR T cell therapy can induce long-term remission of intestinal inflammation in ulcerative colitis, revealing a key role for mucosal B cells and plasmablasts.
- 1 cites
Intratumoral T cell activation can eliminate tumors without tumor-specific T cell receptor involvement, relying solely on paracrine signaling and innate immune responses.
Venetoclax-controlled DROP-CAR T cells enable dose-dependent regulation of tumor targeting, reducing T cell binding to tumor cells in vitro and in vivo.
- Open access
- 2 cites
CAR T cells targeting surface U5 snRNP200, an RNA helicase absent from normal hematopoietic precursors, show efficacy against AML and B-cell ALL in models.
- Open access
Synthetic pH-responsive membranolytic peptide aMP C16-CA50 induces immunogenic cell death in tumor cells, enhancing immune checkpoint blockade therapy in mice.
CytoVI accurately models antibody-based single-cell data, revealing proteins linked to immunoglobulin class-switching and disease-associated T cell states in B cell non-Hodgkin lymphoma.
- Open access
Fifth-generation GD2-CAR T cells secreting anti-PD-L1 scFv show superior cytotoxicity against GD2-low retinoblastoma cells at low effector-to-target ratios.
- Open access
Harmonizing trial design and biomarker integration is essential to improve personalized treatment for large B-cell lymphoma patients.
Mucosal CAR-T cells persist and cause inflammatory remodeling in enterocolitis associated with BCMA CAR-T therapy, with JAK inhibition showing therapeutic promise.
mRNA-encoded CD19-targeting T cell engager achieves complete B cell depletion and durable platelet recovery in refractory immune thrombocytopenia with minimal safety concerns.
- Open access
Heterobifunctional protein binders achieve cell-type-specific targeting with subnanomolar potency via FKBP12-dependent enrichment.
- Open access
PreGame identifies tumour-reactive γδ T-cell receptors with broad reactivity, revealing potential for universal immunotherapy in multiple myeloma and other cancers.
- Open access
Combining cyclophosphamide with immune checkpoint blockade expands effector CD8+ T cell clones, delaying tumor progression in multiple cancer models.
CD4+CD25+FOXP3+ regulatory T cells significantly reduce graft-versus-host disease risk in allogeneic hematopoietic cell transplantation.
Add CAR-T cell therapy research as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6244
- medRxiv1789
- PNAS447
- Sci Adv354
- JAMA268
- Environ Res246
- BMJ196
- Nat Commun173
- Environ Pollution167
- Nature151
- Applied & Environ Microbio145
- Science141
- Lancet128
- Cell Rep127
- NEJM119
- Plant Cell Environ118
- J Exp Bot107
- mBio107
Topics moving, week to 22 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Cancer Immunotherapy and Biomarkers5
- Gut microbiota and health5
- Cancer Genomics and Diagnostics4
- Bacteriophages and microbial interactions4
- CAR-T cell therapy research3
- Lung Cancer Treatments and Mutations3
- Liver Disease Diagnosis and Treatment3
- Dementia and Cognitive Impairment Research3